CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 (Incorporated in Bermuda with members' limited liability 於百慕達註冊成立之成員有限責任公司) (Stock Code 股份代號: 3839) 17 September 2025 The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.ctei.com.hk and on the HKEXnews website at www.hkexnews.hk. If you have requested to receive the Company's Corporate Communications (Note 1) in printed form, the Current Corporate Communication is enclosed. As a ...

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 (Incorporated in Bermuda with members' limited liability 於百慕達註冊成立之成員有限責任公司) (Stock Code 股份代號: 3839) 17 September 2025 Dear registered shareholder(s), Solicitation of electronic contact details To ensure timely receipt of the latest Corporate Communications and Actionable Corporate Communications(Note 2) , the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alte ...

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 Incorporated in Bermuda with members' limited liability • Stock Code : 3839 於百慕達註冊成立之成員有限責任公 司 • 股份代 號：3839 INTERIM REPORT 2025 中期報告 Incorporated in Bermuda with members' limited liability • Stock Code : 3839 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 於百慕達註冊成立之成員有限責任公 司 • 股份代 號：3839 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正 大 企 業 國 際 有 限 公 司 Contents 目 錄 INTERIM REPORT 2025 二零二五年中期報告 01 2 Management Discussion and Analysis 管理層討論及分析 6 Report ...

Core Viewpoint - Charoen Pokphand Enterprises International (03839) has seen a significant increase in stock price, rising over 570% year-to-date, with a current price of 10.02 HKD and a trading volume of 15.47 million HKD [1] Group 1: Strategic Partnership - On August 28, Muyuan Foods and Charoen Group signed a strategic cooperation agreement in Bangkok, Thailand, marking a collaboration between the world's first and third largest pig farming giants [1] - The partnership will focus on strategic planning, business integration, and global layout, promoting deep collaboration in areas such as feed, pig farming, slaughtering, food processing, talent, and capital [1] Group 2: Company Performance - Charoen Pokphand Enterprises International is a subsidiary of Charoen Group and is one of the world's leading producers of chlortetracycline [1] - According to Huaxin Securities, the global market for veterinary chlortetracycline is dominated by two companies, Jinhe Biology and Charoen Biology, which together account for over 90% of global production capacity, indicating a duopoly market structure [1] - The company's financial report shows a 768.36% year-on-year increase in net profit for the first half of the year, primarily driven by significant growth in the group's biochemical business, which focuses on animal health pharmaceutical products and chlortetracycline [1]

Core Viewpoint - Charoen Pokphand International (03839) has seen its stock price increase by over 570% year-to-date, with a recent rise of 8.79% to HKD 10.02, reflecting strong market performance and investor interest [1] Company Summary - Charoen Pokphand International is a subsidiary of Charoen Pokphand Group and is one of the world's leading producers of chlortetracycline [1] - The company reported a significant profit increase of 768.36% year-on-year in the first half of the year, primarily driven by substantial growth in its biochemical business, which focuses on animal health products and chlortetracycline [1] Industry Summary - The strategic partnership signed on August 28 between Muyuan Foods and Charoen Group in Bangkok is seen as a collaboration between the world's first and third largest pig farming giants, aiming for comprehensive cooperation in strategic planning, business integration, and global expansion [1] - The global veterinary chlortetracycline market is characterized by a duopoly, with China’s Jinhe Biology and Charoen Biological accounting for over 90% of global production capacity [1]

公开资料显示，正大企业国际是正大集团子公司，为全球领先的金霉素生产商之一。公司中期业绩显 示，收入约3.23亿美元，同比增长199.44%；公司股东应占溢利1704.6万美元，同比增长768.36%。纯利 增长主要得益于集团生化业务的显著增长，公司生化业务专注于动保化药产品及金霉素。华鑫证券此前 在研报中指出，放眼全球兽用金霉素市场，中国的金河生物（002688）和正大生物共计产能全球占比超 90%，呈现双寡头垄断的竞争格局。 消息面上，据智通财经报道记者从多个信源获悉，为贯彻今年中央一号文件要求，推动生猪产能调控措 施落实落地，农业农村部畜牧兽医局会同国家发展和改革委员会价格司拟于9月16日在北京召开生猪产 能调控企业座谈会。报道指，会议邀请牧原、温氏等25家头部企业参会。据悉，牧原集团近日与正大集 团签订战略合作协议。 正大企业国际(03839)昨日收涨逾15%，今日高见8.87港元，再创历史新高。截至发稿，涨21.49%，报 8.82港元，成交额1979.6万港元。 ...

智通财经APP获悉，正大企业国际(03839)昨日收涨逾15%，今日高见8.87港元，再创历史新高。截至发 稿，涨21.49%，报8.82港元，成交额1979.6万港元。 公开资料显示，正大企业国际是正大集团子公司，为全球领先的金霉素生产商之一。公司中期业绩显 示，收入约3.23亿美元，同比增长199.44%；公司股东应占溢利1704.6万美元，同比增长768.36%。纯利 增长主要得益于集团生化业务的显著增长，公司生化业务专注于动保化药产品及金霉素。华鑫证券此前 在研报中指出，放眼全球兽用金霉素市场，中国的金河生物和正大生物共计产能全球占比超 90%，呈 现双寡头垄断的竞争格局。 消息面上，据智通财经报道记者从多个信源获悉，为贯彻今年中央一号文件要求，推动生猪产能调控措 施落实落地，农业农村部畜牧兽医局会同国家发展和改革委员会价格司拟于9月16日在北京召开生猪产 能调控企业座谈会。报道指，会议邀请牧原、温氏等25家头部企业参会。据悉，牧原集团近日与正大集 团签订战略合作协议。 ...

呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03839 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]

Company Overview - Charoen Pokphand International (03839.HK) closed at HKD 7.6 per share, up 16.21% with a trading volume of 3.08 million shares and a turnover of HKD 22.33 million, showing a volatility of 18.2% [1] - Over the past month, Charoen Pokphand International has seen a cumulative increase of 23.4%, and a year-to-date increase of 338.93%, outperforming the Hang Seng Index by 25.51% [1] - As of June 30, 2025, the company reported total revenue of CNY 2.315 billion, a year-on-year increase of 199.44%, and a net profit attributable to shareholders of CNY 122 million, a year-on-year increase of 768.36% [1] Financial Metrics - The gross profit margin stands at 12.92%, and the debt-to-asset ratio is 36.48% [1] - The company has a price-to-earnings (P/E) ratio of 7.67, ranking 8th in its industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is -1.3 [2] Industry Context - The pharmaceutical and biotechnology industry has a median P/E ratio of 1.52, with other companies in the sector showing varying P/E ratios: - Other Excellent Pharmaceuticals (00858.HK) at 1.41 - Kingsray Biotechnology (01548.HK) at 1.64 - Dongrui Pharmaceutical (02348.HK) at 3.23 - Jilin Changlong Pharmaceutical (08049.HK) at 5.98 - Hutchison China MediTech (00013.HK) at 6.17 [2] Company Background - Charoen Pokphand International is a Hong Kong-listed company involved in biochemical and industrial businesses, established as part of Charoen Pokphand Group since 1995, and is a leading producer of oxytetracycline globally [2] - The company is also a significant stakeholder in one of China's four major Caterpillar distributors, holding 50% of the equity [2] - Charoen Pokphand International has been listed on the Hong Kong Stock Exchange since July 2015 and is a subsidiary of Charoen Pokphand Foods Public Company Limited (CPF.TB), a leading global agribusiness company listed on the Stock Exchange of Thailand [2]